Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: PREVACID

Summary for Tradename: PREVACID

Suppliers: see list8
patent expirations by year for

Pharmacology for Tradename: PREVACID

Drug ClassProton Pump Inhibitor
Mechanism of ActionProton Pump Inhibitors

Clinical Trials for: PREVACID

Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer
Status: Completed Condition: Stomach Ulcer

Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
Status: Completed Condition: Esophagitis; Reflux

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
Status: Completed Condition: Gastroesophageal Reflux Disease

Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants
Status: Completed Condition: Bioavailability

Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain
Status: Withdrawn Condition: Chest Pain; Gastrointestinal Reflux Disease

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
Status: Recruiting Condition: Gastroesophageal Reflux Disease; Erosive Esophagitis

Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn
Status: Completed Condition: Frequent Heartburn

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Status: Completed Condition: Esophagitis, Reflux; Esophagitis, Peptic

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Status: Completed Condition: Esophagitis, Reflux; Esophagitis, Peptic

Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease
Status: Completed Condition: Gastroesophageal Reflux

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
CAPSULE, DELAYED REL PELLETS;ORAL022327May 18, 2009OTCYes<disabled><disabled>
Takeda Pharms Na
FOR SUSPENSION, DELAYED RELEASE;ORAL021281May 3, 2001DISCNNo<disabled><disabled>
Takeda Pharms Na
INJECTABLE;INTRAVENOUS021566May 27, 2004DISCNNo7,396,841*PED<disabled>Y<disabled>
Takeda Pharms Na
lansoprazole; naproxen
CAPSULE, DELAYED REL PELLETS, TABLET;ORAL021507Nov 14, 2003DISCNNo<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: PREVACID

Drugname Dosage Strength RLD Submissiondate
lansoprazoleDelayed-release Orally Disinte15 mg and 30 mgPrevacid12/27/2006
lansoprazoleDelayed-release Pellets/Capsul15 mg and 30 mgPrevacid12/5/2005

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology